irsogladine has been researched along with Stomach Ulcer in 11 studies
irsogladine: RN given refers to parent cpd; MN 1695 refers to maleate salt
Stomach Ulcer: Ulceration of the GASTRIC MUCOSA due to contact with GASTRIC JUICE. It is often associated with HELICOBACTER PYLORI infection or consumption of nonsteroidal anti-inflammatory drugs (NSAIDS).
| Excerpt | Relevance | Reference |
|---|---|---|
| " pylori-positive gastric ulcer were given eradication treatment, then assigned randomly to a treatment group [given 4 mg/day irsogladine maleate (n = 150)] or a control group [given a placebo (n = 161)]." | 9.14 | Clinical trial: irsogladine maleate, a mucosal protective drug, accelerates gastric ulcer healing after treatment for eradication of Helicobacter pylori infection--the results of a multicentre, double-blind, randomized clinical trial (IMPACT study). ( Goto, H; Haruma, K; Hiraishi, H; Miwa, H, 2010) |
| "This study was conducted to investigate the inhibitory effect of irsogladine maleate (IM) on gastric ulcers induced by ethanol and hydrochloric acid (HCl)." | 8.02 | Gastroprotective effects of irsogladine maleate on ethanol/hydrochloric acid induced gastric ulcers in mice. ( Kim, JH; Kwon, SC, 2021) |
| " Adverse effects were also compared." | 6.90 | The efficacy and safety of irsogladine maleate in nonsteroidal anti-inflammatory drug or aspirin-induced peptic ulcer and gastritis. ( Choi, SC; Hong, SJ; Jo, YJ; Kim, GH; Kim, HJ; Kim, JH; Kim, JI; Kim, JW; Kim, N; Kim, SG; Kwon, JG; Park, KS; Shim, KN; Shin, JE, 2019) |
| "Irsogladine has previously been shown to accelerate the healing of gastric ulcers after H." | 6.76 | Comparison of the efficacy of irsogladine maleate and famotidine for the healing of gastric ulcers after Helicobacter pylori eradication therapy: a randomized, controlled, prospective study. ( Abe, H; Arita, T; Fujioka, T; Kodama, M; Mizukami, K; Murakami, K; Okimoto, T; Shuto, M; Tanahashi, J, 2011) |
| " pylori-positive gastric ulcer were given eradication treatment, then assigned randomly to a treatment group [given 4 mg/day irsogladine maleate (n = 150)] or a control group [given a placebo (n = 161)]." | 5.14 | Clinical trial: irsogladine maleate, a mucosal protective drug, accelerates gastric ulcer healing after treatment for eradication of Helicobacter pylori infection--the results of a multicentre, double-blind, randomized clinical trial (IMPACT study). ( Goto, H; Haruma, K; Hiraishi, H; Miwa, H, 2010) |
| "This study was conducted to investigate the inhibitory effect of irsogladine maleate (IM) on gastric ulcers induced by ethanol and hydrochloric acid (HCl)." | 4.02 | Gastroprotective effects of irsogladine maleate on ethanol/hydrochloric acid induced gastric ulcers in mice. ( Kim, JH; Kwon, SC, 2021) |
| "The effect of 2,4-diamino-6-(2,5-dichlorophenyl)-s-triazine maleate (MN-1695) on various experimental gastric ulcers and gastric secretion in experimental animals was compared with that of cimetidine and cetraxate." | 3.67 | Effect of 2,4-diamino-6-(2,5-dichlorophenyl)-s-triazine maleate (MN-1695) on gastric ulcers and gastric secretion in experimental animals. ( Aratani, S; Enomoto, H; Kimura, K; Mimura, K; Nomura, A; Ueda, F, 1984) |
| " Adverse effects were also compared." | 2.90 | The efficacy and safety of irsogladine maleate in nonsteroidal anti-inflammatory drug or aspirin-induced peptic ulcer and gastritis. ( Choi, SC; Hong, SJ; Jo, YJ; Kim, GH; Kim, HJ; Kim, JH; Kim, JI; Kim, JW; Kim, N; Kim, SG; Kwon, JG; Park, KS; Shim, KN; Shin, JE, 2019) |
| "Irsogladine has previously been shown to accelerate the healing of gastric ulcers after H." | 2.76 | Comparison of the efficacy of irsogladine maleate and famotidine for the healing of gastric ulcers after Helicobacter pylori eradication therapy: a randomized, controlled, prospective study. ( Abe, H; Arita, T; Fujioka, T; Kodama, M; Mizukami, K; Murakami, K; Okimoto, T; Shuto, M; Tanahashi, J, 2011) |
| "Pretreatment with irsogladine maleate markedly reduced the number and severity of these lesions in a dose-dependent manner." | 1.35 | Irsogladine maleate suppresses indomethacin-induced elevation of proinflammatory cytokines and gastric injury in rats. ( Kageyama, K; Kyoi, T; Tajima, K; Zhang, X, 2008) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 3 (27.27) | 18.7374 |
| 1990's | 1 (9.09) | 18.2507 |
| 2000's | 3 (27.27) | 29.6817 |
| 2010's | 3 (27.27) | 24.3611 |
| 2020's | 1 (9.09) | 2.80 |
| Authors | Studies |
|---|---|
| Kwon, SC | 1 |
| Kim, JH | 2 |
| Shim, KN | 1 |
| Kim, JI | 1 |
| Kim, N | 1 |
| Kim, SG | 1 |
| Jo, YJ | 1 |
| Hong, SJ | 1 |
| Shin, JE | 1 |
| Kim, GH | 1 |
| Park, KS | 1 |
| Choi, SC | 1 |
| Kwon, JG | 1 |
| Kim, HJ | 1 |
| Kim, JW | 1 |
| Zhang, X | 2 |
| Tajima, K | 2 |
| Kageyama, K | 1 |
| Kyoi, T | 6 |
| Hiraishi, H | 1 |
| Haruma, K | 1 |
| Miwa, H | 1 |
| Goto, H | 1 |
| Murakami, K | 1 |
| Okimoto, T | 1 |
| Kodama, M | 1 |
| Tanahashi, J | 1 |
| Mizukami, K | 1 |
| Shuto, M | 1 |
| Abe, H | 1 |
| Arita, T | 1 |
| Fujioka, T | 1 |
| Oka, M | 1 |
| Noda, K | 1 |
| Ukai, Y | 2 |
| Kitazawa, S | 1 |
| Ueda, F | 4 |
| Aratani, S | 1 |
| Mimura, K | 1 |
| Kimura, K | 4 |
| Nomura, A | 1 |
| Enomoto, H | 2 |
| Watanabe, M | 1 |
| Hirata, Y | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Compare the Effect of Eupatilin and Rebamipide on the Prevention of Gastroenteropathy in Patients With NSAIDs and Low Dose Steroid: A Single-center, Randomized, Open Labeled, Pilot Study[NCT04885751] | Phase 4 | 50 participants (Anticipated) | Interventional | 2021-06-01 | Not yet recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
3 trials available for irsogladine and Stomach Ulcer
8 other studies available for irsogladine and Stomach Ulcer
| Article | Year |
|---|---|
Gastroprotective effects of irsogladine maleate on ethanol/hydrochloric acid induced gastric ulcers in mice.
Topics: Animals; Ethanol; Gastric Mucosa; Hydrochloric Acid; Mice; Stomach Ulcer; Triazines | 2021 |
Irsogladine maleate suppresses indomethacin-induced elevation of proinflammatory cytokines and gastric injury in rats.
Topics: Animals; Anti-Ulcer Agents; Cyclic Nucleotide Phosphodiesterases, Type 4; Cytokines; Disease Models, | 2008 |
Irsogladine prevents monochloramine-induced gastric mucosal lesions by improving the decrease in mucosal blood flow due to the disturbance of nitric oxide synthesis in rats.
Topics: Animals; Chloramines; Dose-Response Relationship, Drug; Gastric Mucosa; Male; Nitric Oxide; Rats; Ra | 2003 |
Phosphodiesterase type IV inhibitors prevent ischemia-reperfusion-induced gastric injury in rats.
Topics: 3',5'-Cyclic-AMP Phosphodiesterases; 4-(3-Butoxy-4-methoxybenzyl)-2-imidazolidinone; Animals; Anti-U | 2004 |
Effect of 2,4-diamino-6-(2,5-dichlorophenyl)-s-triazine maleate (MN-1695) on gastric ulcers and gastric secretion in experimental animals.
Topics: Acetates; Acetic Acid; Animals; Anti-Ulcer Agents; Cimetidine; Female; Gastric Acid; Gastric Mucosa; | 1984 |
Changes in cyclic AMP content of rat gastric mucosa induced by ulcerogenic stimuli--in relation to the antiulcer activity of irsogladine maleate.
Topics: Animals; Anti-Ulcer Agents; Aspirin; Bucladesine; Cyclic AMP; Gastric Acid; Gastric Mucosa; Male; Py | 1991 |
[Synergistic effect of irsogladine maleate and histamine H2-receptor antagonists on experimental gastric ulcers in rats].
Topics: Animals; Anti-Ulcer Agents; Drug Synergism; Drug Therapy, Combination; Histamine H2 Antagonists; Mal | 1989 |
[Protective effect of dicloguamine maleate (MN-1695) on HCl-induced gastric mucosal damage in rats--histologic studies].
Topics: Animals; Anti-Ulcer Agents; Gastric Mucosa; Hydrochloric Acid; Male; Rats; Rats, Inbred Strains; Sto | 1987 |